While the expression of TRM markers, especially CD103, in tumor-infiltrating T cells is associated with a stronger antitumor effect in various solid malignant tumors, as described above [69,70,71,72,73,74], benign T cells in CTCL lesions possess less TRM (CD69+ CD103+) phenotype [97,118]. The gene discussed is ITGAE; the disease is neoplasm.